Weight Gain During Long-Term Treatment of Obsessive-Compulsive Disorder: A Prospective Comparison Between Serotonin Reuptake Inhibitors
The DOI matches its Crossref record, with a small difference in title or year.
Abstract
BACKGROUND: The effect of extended anti-depressant treatment on weight has been poorly investigated. Also unknown is whether different compounds have differential effects. The aim of the present study was to assess changes in weight in obsessive-compulsive disorder (OCD) patients treated for 2.5 years with clomipramine or selective serotonin reuptake inhibitors. METHOD: 138 DSM-IV OCD patients who responded to 6-month acute treatment at the Mood and Anxiety Disorders Unit, Department of Neuroscience, University of Turin, Italy, were followed-up for 2 years while receiving open-label clomipramine, citalopram, fluoxetine, fluvoxamine, paroxetine, or sertraline. Patients were consecutively recruited and followed from May 1998 to March 2003. The mean percentage change in weight was compared for each group, as was the proportion of patients who had a > or = 7% weight increase from baseline. RESULTS: At the end of the 2.5-year study period, patients had gained a mean of 2.5% of their body weight with respect to baseline (1.58 kg); 14.5% of the total sample experienced a significant (> or = 7%) weight increase. Within each but the fluoxetine treatment group, paired t tests showed a significant increase in weight from baseline to final visit. Analysis of variance showed a significant difference between treatment groups (p = .009), with clomipramine being associated with the highest weight increase and fluoxetine and sertraline with the lowest. A higher proportion of clomipramine-treated patients (34.8%) gained > or = 7% in weight as compared with sertraline and fluoxetine, which accounted for the lowest percentage of patients with a significant weight gain (4.5% and 8.7%, respectively), although this difference was not statistically significant. CONCLUSION: Risk of weight gain during extended serotonin reuptake inhibitor treatment for OCD differs depending on which compound is used. The differences among antiobsessive drugs may affect compliance with medication and health risks.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Although widely used and efficacious [8–10], SRI use long-term is associated with adverse side effects [11–14]”
From Unified protocol for the discontinuation of long-term serotonin reuptake inhibitors in obsessive compulsive disorder: Study protocol and methods (2018) · cites this paper as [14]
Citations
Cites
Still being checked.
Cited by
Practice Guideline for the Treatment of Patients With Obsessive-Compulsive Disorder
(2008) · APA Practice Guidelines for the Treatment of Psychiatric Disorders: Comprehensive Guidelines and Guideline Watches · doi:10.1176/appi.books.9780890423363.149114 · Cited by 1,028
“…OCD (N=138) 2 years after they had completed a 6-month treatment period with clomipramine or SSRIs (not including escitalopram) found clomipramine associated with the greatest weight increase (2.9±2.6 kg), and fluoxetine (0.5±2.4 kg) and sertraline (1.0±1.7 kg) with the least (Maina et al. 2004).”
BackgroundInfluentialDepression and the Link with Cardiovascular Disease
Dhar, A. K., & Barton, D. A. (2016) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2016.00033 · Cited by 400
Antidepressant Medications and Weight Change: A Narrative Review
Gill, H., Gill, B., El‐Halabi, S., Chen‐Li, D., Lipsitz, O., Rosenblat, J. D., Van Rheenen, T. E., Rodrigues, N. B., Mansur, R. B., Majeed, A., et al. (2020) · Obesity · doi:10.1002/oby.22969 · Cited by 193
Evidence-based pharmacological treatment of generalized anxiety disorder
Baldwin, D. S., Waldman, S., & Allgulander, C. (2011) · The International Journal of Neuropsychopharmacology · doi:10.1017/s1461145710001434 · Cited by 168
Update in the methodology of the chronic stress paradigm: internal control matters
Strekalova, T., Couch, Y., Kholod, N., Boyks, M., Malin, D., Leprince, P., & Steinbusch, H. M. (2011) · Behavioral and Brain Functions · doi:10.1186/1744-9081-7-9 · Cited by 163
“Restoration of body weight by antidepressant treatment, particularly citalopram, in animal models of depression has been shown to to accompany recovery from a depressive-like state [ 130 ].”
Background
Metadata
- Authors
- Maina, G., Albert, U., Salvi, V., & Bogetto, F.
- Affiliations
- University of Turin (IT)
- Venue
- The Journal of Clinical Psychiatry
- Publisher
- Physicians Postgraduate Press, Inc
- Published
- 2004-10-15
- Volume
- 65
- Issue
- 10
- Pages
- 1365-1371
- ISSN
- 0160-6689 (ISSN-L)
- OpenAlex
- W2034186473
- Cited by
- 79
- References
- 0
- Citations by year
- 2026: 1 · 2025: 1 · 2024: 1 · 2023: 1 · 2022: 2 · 2021: 2 · 2020: 3 · 2019: 2 · 2018: 4 · 2017: 1 · 2016: 7 · 2015: 2 · 2014: 3 · 2013: 5 · 2012: 3
- FWCI
- 6.79
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- The Journal of Clinical Psychiatry (publishedVersion)
- PubMed (publishedVersion)
- Institutional Research Information System University of Turin (University of Turin) (submittedVersion)
- Topics
- Social Sciences › Psychology › Clinical Psychology › Obsessive-Compulsive Spectrum Disorders
- Social Sciences › Psychology › Clinical Psychology › Eating Disorders and Behaviors
- Health Sciences › Medicine › Pharmacology (medical) › Pharmacology and Obesity Treatment
- Keywords
- obsessive-compulsive disorder, weight gain, clomipramine, selective serotonin reuptake inhibitors, fluoxetine, sertraline, citalopram, fluvoxamine, paroxetine, long-term antidepressant treatment, medication adherence
- MeSH terms
- Adult, Ambulatory Care, Clomipramine, Female, Fluoxetine, Follow-Up Studies, Humans, Male, Obesity, Obsessive-Compulsive Disorder, Patient Compliance, Prospective Studies, Risk Factors, Citalopram, Weight Gain, Fluvoxamine, Selective Serotonin Reuptake Inhibitors, Paroxetine, Sertraline
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Weight Gain During Long-Term Treatment of Obsessive-Compulsive Disorder: A Prospective Comparison Between Serotonin Reuptake Inhibitors. https://app.cochat.ai/papers/10.4088/jcp.v65n1011
- The paper
- Maina, G., Albert, U., Salvi, V., & Bogetto, F. (2004). Weight Gain During Long-Term Treatment of Obsessive-Compulsive Disorder: A Prospective Comparison Between Serotonin Reuptake Inhibitors. The Journal of Clinical Psychiatry. https://doi.org/10.4088/jcp.v65n1011
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.